Initially doing business a Galileo Laboratories and organized around evidence-based nutraceuticals and pharmaceuticals, the firm was renamed Galileo Pharmaceuticals, Inc., with a flcous shifted to the discovery and development of therapeutics targeting redox signaling metabolic pathways. The company is developing a pipeline of treatments for diabetes and arthritis. Principals of Galileo are relocated to other concerns but with no clear indication of what happened to the firm itself
